Athenen Therapeutics
Boston, US · Founded 2019 · Delaware corporation
Founders & leadership
AL
Andrew LevinNamed on SEC filing
SR
Sarah ReedNamed on SEC filing
JS
James SchneiderNamed on SEC filing
SE
Sari EpsteinNamed on SEC filing
AR
Adam RosenbergNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$12M disclosed across 1 round · 2019
▶$12MraisedJul 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$12MraisedJul 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LevinDirector
- Sarah ReedExecutive Officer
- James SchneiderExecutive Officer
- Sari EpsteinExecutive Officer
- Adam RosenbergExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $12M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Athenen Therapeutics raised?
- Athenen Therapeutics has disclosed $12M raised across 1 round.
- Where is Athenen Therapeutics headquartered?
- Athenen Therapeutics is headquartered in Boston, US.